Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of June 2020, with the report dated June 16, 2020. The filing serves as a transaction notification regarding insider trading activity rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a specific securities transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the acquisition of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Transaction Details and Commentary
- Individual: Mr. P Thomson, President, Global Affairs.
- Transaction Type: Acquisition of Ordinary Shares following the exercise of options granted on November 30, 2016, under the Company's ShareSave Plan.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Volume: 277 shares.
- Price: £12.95 per share.
- Date: June 12, 2020.
- Location: London Stock Exchange (XLON).
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies beyond the standard transaction disclosure.
Investor Verification Points
- Verify the total number of shares held by Mr. P Thomson post-transaction to assess overall insider ownership concentration.
- Confirm the terms of the ShareSave Plan referenced (granted November 30, 2016) to understand the vesting schedule and strike price context.
- Note that this filing does not reflect the company's broader financial performance for the period; refer to Form 20-F or interim reports for financial metrics.